Concordia Healthcare Corp.: Is This Stock as Bad as Valeant Pharmaceuticals Intl Inc.?

Concordia Healthcare Corp. (TSX:CRX)(NASDAQ:CXRX) has fallen in sympathy with Valeant Pharmaceuticals Intl Inc. (TSX:VRX)(NYSE:VRX). Is now a buying opportunity?

| More on:
The Motley Fool

The big story last week was the absolute pounding that Valeant Pharmaceuticals Intl Inc. (TSX:VRX)(NYSE:VRX) shares took.

You’re likely familiar with the story. Short-selling firm Citron Research essentially said Valeant was a fraud. Allegations of fraud came to light when Citron discovered a filing from a pharmacy named R&O that claimed Valeant billed it for drugs it never received or sold. R&O Pharmacy is also owned by a company called Philidor, a company that Valeant admits to having a close-enough relationship with that it consolidates Philidor’s results in its own financial reports.

Citron even went as far as comparing Valeant to Enron, since the latter used sales-stuffing techniques to inflate revenue.

This was just the latest piece of news to hurt Valeant. About a month ago the company first came under fire because of its strategy to acquire competitors and inflate the price of their drugs. Democratic presidential hopeful Hillary Clinton vowed that a White House led by her would crack down on this practice.

Valeant isn’t the only drug company with this type of business; it’s just the most famous. Concordia Heathcare Corp. (TSX:CRX)(NASDAQ:CXRX) has been crushed in sympathy, falling more than 60% since peaking at $110 per share in the first part of September.

Should Concordia investors be concerned, or is this just a case of throwing out the baby with the bathwater? Let’s take a closer look.

A big acquisition

Adding to this mess is Concordia’s huge new acquisition of Amdipharm, a U.K.-based pharma company which has operations in more than 100 different countries. Like with Concordia and Valeant, Amdipharm follows a very familiar business model. It acquires the rights to drugs, slashes R&D expenses, increases prices, and uses other synergies to make these medicines more profitable.

These similarities between the two companies are the big reason why shares of Concordia have performed so poorly lately. When the market gets spooked, investors head for the exits and ask questions later. Besides, many long-term holders have still made money on the stock. It’s done that well, even after falling more than 60%.

Management is bullish on the big acquisition. The company predicts adjusted EBITDA will soar in 2016, jumping up to between US$510 and US$540 million, which, on the surface, looks like a very reasonable multiple for a company with a market cap of just $1.82 billion.

The big issue is with the debt needed to make the big purchase. In today’s market, anything above a 5% interest rate is considered high risk. Concordia was forced to pay an average of 7.5% for the US$2.8 billion it needed to finance the deal. In total, Concordia will owe more than US$4.1 billion when it officially closes.

The bull case

It isn’t all bad news for Concordia. The big acquisition does look to be a pretty good deal, provided it doesn’t drown under the debt load.

The acquisition further diversifies its product base, with no one drug accounting for more than 10% of its sales. It also gives the company access to new markets for some of its existing drugs. As well, Amnipharm has outsourced much of its business to India, a low-cost area. The company plans further cost cuts by outsourcing more things to the country.

Concordia has a track record of successfully integrating these types of acquisitions, too. Since May 2013, it has made six separate transactions much like this one. These have all gone relatively smoothly.

Should you buy Concordia?

The reason why Concordia shares are down so much is because the market has overreacted to the Valeant rumours. It’s that simple.

That said, there are plenty of other reasons to avoid Concordia right now. The debt load is very high. It could see pressure from U.S. lawmakers that limit price increases. And if Valeant continues to be targeted by short-sellers–either rightfully or wrongfully–it will react in sympathy. For those reasons, I’d avoid the stock as well as Valeant.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Nelson Smith has no position in any stocks mentioned. Tom Gardner owns shares of Valeant Pharmaceuticals. The Motley Fool owns shares of Valeant Pharmaceuticals.

More on Investing

A cannabis plant grows.
Cannabis Stocks

Canopy Growth Stock Is Rising But I’m Worried About This One Thing

Canopy Growth stock is soaring as the legalization effort makes real progress in both Germany and the United States.

Read more »

young woman celebrating a victory while working with mobile phone in the office
Investing

3 Roaring Stocks to Hold for the Next 20 Years

These top TSX stocks are excellent long-term buys, given their multi-year growth potential and solid underlying businesses.

Read more »

Two seniors float in a pool.
Dividend Stocks

TFSA: How to Earn $1,890 in Annual Tax-Free Income

Plunk these investments into your TFSA to earn passive income and avoid the taxman.

Read more »

grow dividends
Investing

Here’s My Top 3 TSX Stocks to Buy Right Now

Even though the TSX has been rising, there are still some good bargains out there. Here are three top compounding…

Read more »

Target. Stand out from the crowd
Investing

Prediction: This Canadian Growth Stock Could Double by 2030

Alimentation Couche-Tard (TSX:ATD) is a top growth stock that could do well over the next six or so years.

Read more »

Businessman holding AI cloud
Tech Stocks

Could Investing $20,000 in Nvidia Make You a Millionaire?

Nvidia stock has made investors millionaires in the last 10 years. Is it too late to invest to become a…

Read more »

Engineers walk through a facility.
Dividend Stocks

1 TSX Stock I Wouldn’t Touch With a 10-Foot Pole

AtkinsRéalis (TSX:ATRL) is one TSX stock I'd never invest in.

Read more »

money cash dividends
Stocks for Beginners

Have $500? 3 Absurdly Cheap Stocks Long-Term Investors Should Buy Right Now

If you're looking for cheap stocks, these three have a huge future ahead of them, all while costing far less…

Read more »